Vor Bio (Nasdaq: VOR) announced inducement grants on April 1, 2026 for nine newly hired employees: 42,650 stock options and 9,050 RSUs under the 2023 Inducement Plan.
The options carry a $17.39 exercise price (closing price on grant date), a 10-year term, and a four-year vesting schedule (25% after 12 months, then monthly). RSUs vest over four years with 25% after 12 months and quarterly thereafter, all subject to continued employment and award agreements.
Loading...
Loading translation...
Positive
None.
Negative
None.
News Market Reaction – VOR
+3.80%
23 alerts
+3.80%News Effect
+5.6%Peak Tracked
-2.8%Trough Tracked
+$35MValuation Impact
$942.76MMarket Cap
0.6xRel. Volume
On the day this news was published, VOR gained 3.80%, reflecting a moderate positive market reaction.
Argus tracked a peak move of +5.6% during that session.
Argus tracked a trough of -2.8% from its starting point during tracking.
Our momentum scanner triggered 23 alerts that day, indicating elevated trading interest and price volatility.
This price movement added approximately $35M to the company's valuation, bringing the market cap to $942.76M at that time.
This announcement details stock options on 42,650 shares and 9,050 RSUs granted to 9 new employees a...
Analysis
This announcement details stock options on 42,650 shares and 9,050 RSUs granted to 9 new employees as inducement awards under Nasdaq Listing Rule 5635(c)(4). These awards, with a $17.39 exercise price and four-year vesting, follow a period of substantial clinical and financing activity, including a $75 million private placement and Phase 3 trial progress. Investors may track how equity compensation, registered resale shares, and future clinical milestones interact with the existing capital structure.
Key Figures
Current share price:$17.39Stock options granted:42,650 sharesRSUs granted:9,050 shares+5 more
8 metrics
Current share price$17.39Closing price used as stock option exercise price on grant date
Stock options granted42,650 sharesInducement grant to new employees under 2023 Inducement Plan
RSUs granted9,050 sharesRestricted stock units as inducement awards to new employees
New employees9 employeesRecipients of stock options and RSUs as material inducements
Option term10 yearsDuration of stock options granted under Inducement Plan
Initial vesting cliff25% after 12 monthsApplies to both options and RSUs, subject to continued employment
Option vesting tail36 months monthlyRemaining stock options vest monthly over following 36 months
RSU vesting tail36 months quarterlyRemaining RSUs vest quarterly over following 36 months
Participation and presentation at the 46th Annual TD Cowen Health Care Conference.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Pattern Detected
Recent VOR news, including Phase 3 trial progress, financing, and corporate events, has generally seen positive single-digit to low-teens price moves, with no consistent pattern of selling on good news.
Recent Company History
Over recent months, Vor Bio has reported multiple catalysts, including a Phase 3 UPSTREAM SjD trial first patient dosed on Mar 30, 2026 and a $75 million private placement announced on Mar 27, 2026. Earnings on Mar 30, 2026 highlighted substantial cash and investment levels and projected funding into early 2029. Earlier, inducement grants and conference participation were disclosed. Compared with today’s inducement grants, prior news involved more fundamental clinical and financing milestones, each met with generally positive price reactions.
"granted as material inducements to employment with Vor Bio in accordance with Nasdaq Listing Rule 5635(c)(4)"
NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.
restricted stock unitsfinancial
"stock options to purchase an aggregate of 42,650 shares of Vor Bio’s common stock and restricted stock units (“RSUs”)"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
stock optionsfinancial
"Compensation Committee of the Board of Directors granted stock options to purchase an aggregate of 42,650 shares"
Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.
BOSTON, April 01, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that, on April 1, 2026, the Compensation Committee of the Board of Directors granted stock options to purchase an aggregate of 42,650 shares of Vor Bio’s common stock and restricted stock units (“RSUs”) representing the right to receive an aggregate of 9,050 shares of Vor Bio’s common stock to 9 newly hired employees. The foregoing stock options and RSUs were granted as material inducements to employment with Vor Bio in accordance with Nasdaq Listing Rule 5635(c)(4) and were granted under the Vor Biopharma Inc. 2023 Inducement Plan (the “Inducement Plan”).
The stock options have a ten-year term, and an exercise price of $17.39 per share, which is equal to the closing price of Vor Bio’s common stock on the grant date of the stock options. The options will vest over a four-year period, with 25% of the shares vesting after 12 months and the remaining shares vesting monthly over the following 36 months, subject to the employees’ continued employment with Vor Bio on such vesting dates. The RSUs will vest over a four-year period, with 25% of the shares vesting after 12 months and the remaining shares vesting quarterly over the following 36 months, subject to the employees’ continued employment with Vor Bio on such vesting dates. The options and RSUs are subject to the terms and conditions of the Inducement Plan and the terms and conditions of an award agreement covering the grants.
About Vor Bio
Vor Bio is a clinical-stage biotechnology company transforming the treatment of autoimmune diseases. The company is focused on rapidly advancing telitacicept, a novel dual-target fusion protein, through Phase 3 clinical development and potential commercialization to address serious autoantibody-driven conditions worldwide. For more information visit www.vorbio.com
Media & Investor Contacts:
Carl Mauch
cmauch@vorbio.com
FAQ
What did Vor Bio (VOR) grant on April 1, 2026 to new employees?
Vor Bio granted 42,650 stock options and 9,050 RSUs to nine new hires. According to the company, the awards were inducements under the 2023 Inducement Plan and subject to award agreements and vesting conditions.
What is the exercise price and term of the VOR stock options granted April 1, 2026?
The options have an exercise price of $17.39 and a 10-year term. According to the company, $17.39 equals Vor Bio's closing stock price on the grant date and options expire ten years from grant.
How do the VOR option vesting schedules work for the April 1, 2026 grants?
Options vest over four years: 25% after 12 months, then monthly for 36 months. According to the company, vesting is contingent on continued employment and governed by the award agreement and Inducement Plan.
What is the RSU vesting schedule for Vor Bio's April 1, 2026 grants?
RSUs vest over four years with 25% after 12 months and the remainder vesting quarterly over 36 months. According to the company, RSU payouts depend on continued employment and the terms of the award agreement.
Under which plan were Vor Bio's April 1, 2026 inducement grants made (VOR)?
The grants were made under the Vor Biopharma 2023 Inducement Plan as Nasdaq Rule 5635(c)(4) inducements. According to the company, the awards comply with Nasdaq listing rule requirements for new-hire inducements.
How many employees received inducement equity from Vor Bio (VOR) on April 1, 2026?
Nine newly hired employees received inducement awards on April 1, 2026. According to the company, those nine hires collectively received 42,650 options and 9,050 RSUs under the Inducement Plan.
